...
首页> 外文期刊>Circulation research: a journal of the American Heart Association >Identifying the Transcriptome Signatures of Calcium Channel Blockers in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
【24h】

Identifying the Transcriptome Signatures of Calcium Channel Blockers in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

机译:鉴定人诱导多能干细胞衍生心肌细胞中钙通道阻滞剂的转录组签名

获取原文
获取原文并翻译 | 示例
           

摘要

Rationale: Calcium channel blockers (CCBs) are an important class of drugs in managing cardiovascular diseases. Patients usually rely on these medications for the remainder of their lives after diagnosis. Although the acute pharmacological actions of CCBs in the hearts are well-defined, little is known about the drug-specific effects on human cardiomyocyte transcriptomes and physiological alterations after long-term exposure. Objective: This study aimed to simulate chronic CCB treatment and to examine both the functional and transcriptomic changes in human cardiomyocytes. Methods and Results: We differentiated cardiomyocytes and generated engineered heart tissues from 3 human induced pluripotent stem cell lines and exposed them to 4 different CCBs-nifedipine, amlodipine, diltiazem, and verapamil-at their physiological serum concentrations for 2 weeks. Without inducing cell death and damage to myofilament structure, CCBs elicited line-specific inhibition on calcium kinetics and contractility. While all 4 CCBs exerted similar inhibition on calcium kinetics, verapamil applied the strongest inhibition on cardiomyocyte contractile function. By profiling cardiomyocyte transcriptome after CCB treatment, we identified little overlap in their transcriptome signatures. Verapamil is the only inhibitor that reduced the expression of contraction-related genes, such as MYH (myosin heavy chain) and troponin I, consistent with its depressive effects on contractile function. The reduction of these contraction-related genes may also explain the responsiveness of patients with hypertrophic cardiomyopathy to verapamil in managing left ventricular outflow tract obstruction. Conclusions: This is the first study to identify the transcriptome signatures of different CCBs in human cardiomyocytes. The distinct gene expression patterns suggest that although the 4 inhibitors act on the same target, they may have distinct effects on normal cardiac cell physiology.
机译:理由:钙通道阻滞剂(CCBS)是管理心血管疾病中的重要药物。患者通常依赖于这些药物的诊断后其余的生命。虽然CCBS在心中的急性药理作用是明确定义的,但对于长期暴露后的人心肌细胞转录瘤和生理改变的药物特异性效果很少。目的:本研究旨在模拟慢性CCB治疗,并检查人心肌细胞的功能性和转录组变化。方法和结果:我们将心肌细胞和生成的生成多能干细胞系的生成心脏组织分化,并将其暴露于4种不同的CCBS-NiFemeDipine,Amlodipine,Diltiazem和Verapamil-在其生理血清浓度下进行2周。在不诱导细胞死亡和透明丝结构的损伤,CCBS在钙动力学和收缩性上引发了含线的抑制。虽然所有4个CCBS对钙动力学的抑制作用相似,因此维拉帕米对心肌细胞收缩功能的最强抑制性。通过在CCB处理后分析心肌细胞转录组,我们在转录组签名中鉴定了几乎没有重叠。维拉帕米是唯一减少收缩相关基因的表达的唯一抑制剂,例如MYH(肌球蛋白重链)和肌钙蛋白I,与其对收缩功能的抑郁作用一致。这些收缩相关基因的减少也可以解释患者对患有血管内流体病的患者对维拉帕米的反应能力,在管理左心室流出道梗阻中。结论:这是第一项识别人心肌细胞中不同CCB的转录组签名的研究。不同的基因表达模式表明,尽管4个抑制剂作用于同一目标,但它们对正常心细胞生理学可能具有明显的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号